Compare Endeavour Silver Corp (EXK) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Novo Nordisk A/S — how do they compare? Endeavour Silver Corp trades at $8.72 (market cap $2.54B), while Novo Nordisk A/S trades at $38.38 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 65.1× Endeavour Silver Corp's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Endeavour Silver Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Endeavour Silver Corp for 25 Days and Novo Nordisk A/S for 116 Days on average.
| EXK | NVO | |
|---|---|---|
Market Cap | $2.54B | $165.31B |
Volume | 7,077,330 | 11,432,838 |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $63.98 |
52-Week Low | $7.07 | $35.29 |
Typical Hold Time | 25 Days | 116 Days |
Enterprise Value | $2.54B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $8.77, up 5.41% today, showing mixed technical signals with a bearish moving average trend but neutral oscillators. The company reported strong Q1 2026 earnings beat but missed Q2 expectations, with revenue projected to grow from $468M in 2025 to $737M in 2026. Recent developments include operational progress at Terronera mine and resolution of blockade issues, while maintaining a 78.57% analyst buy rating.
EXK presents growth potential through mine expansions and favorable silver prices, but faces execution risks from operational disruptions and negative 2025 net income. The stock's high P/E ratio of 42.85 suggests premium valuation, requiring careful monitoring of production targets and cost management for sustained profitability improvement.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
